Research programme: CNS disorders therapies - Novartis

Drug Profile

Research programme: CNS disorders therapies - Novartis

Alternative Names: JN403; JN711

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Class Cyclopentanes; Pyrimidines; Pyrrolidinones; Small molecules
  • Mechanism of Action Alpha7 nicotinic acetylcholine receptor agonists; GABA modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Anxiety disorders; CNS disorders; Cocaine abuse

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Anxiety-disorders in Switzerland (PO)
  • 16 Jul 2016 No recent reports of development identified for research development in CNS-disorders in Switzerland
  • 01 Sep 2011 Pharmacodynamics data from a preclinical trial in Anxiety disorders presented at the 242nd American Chemical Society National Meeting (242nd-ACS-2011)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top